Clinical Report: Current Evidence and Future Directions of Neoadjuvant Treatments for Clear Cell Renal Cell Carcinoma
Background
Renal cell carcinoma (RCC) is a significant health concern, with clear cell renal cell carcinoma (ccRCC) being the most common subtype. Despite advances in imaging and treatment, many patients still present with advanced disease.
Data Highlights
No specific numerical data or trial results were provided in the source material.
Key Findings
Neoadjuvant therapy may induce tumor cytoreduction and downstaging, facilitating easier surgical resection.
Combination strategies of immune checkpoint inhibitors (ICI) and tyrosine kinase inhibitors (TKI) have shown improved survival in metastatic RCC.
Neoadjuvant systemic therapy can modulate the tumor microenvironment, enhancing immune responses against ccRCC.
Current guidelines indicate that neoadjuvant systemic therapy is still under investigation and should be considered within clinical trials.
Phase 3 trials, such as PROSPER, have shown similar recurrence-free survival between neoadjuvant therapy and surgery alone.
Clinical Implications
Further research is needed to establish the benefits of neoadjuvant therapies in ccRCC management.
Conclusion
Continued investigation is essential to clarify the role of neoadjuvant treatments in clinical practice.
by Thomas McMaster, Niall McVeigh, David C. Chen, Abdullah Al-Khanaty, Kieran Sandhu, Jonathon Carll, Dixon T. Woon, Declan G. Murphy, Nathan Lawrentschuck, Lewis Au, Muhammad Ali, Shankar Siva, Marlon Perera
